Amussen Hunsaker Associates LLC Pds Biotechnology Corp Transaction History
Amussen Hunsaker Associates LLC
- $715 Million
- Q3 2024
A detailed history of Amussen Hunsaker Associates LLC transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Amussen Hunsaker Associates LLC holds 75,016 shares of PDSB stock, worth $128,277. This represents 0.04% of its overall portfolio holdings.
Number of Shares
75,016
Previous 75,016
-0.0%
Holding current value
$128,277
Previous $219,000
30.59%
% of portfolio
0.04%
Previous 0.03%
Shares
9 transactions
Others Institutions Holding PDSB
# of Institutions
64Shares Held
4.32MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$2.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$832,7130.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$709,8430.0% of portfolio
-
Inspirion Wealth Advisors, LLC344KShares$588,9130.18% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$400,4970.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $48.7M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...